Document is current
Any future updates will be listed below
-
Authors
Nikishina, Irina P. http://orcid.org/0000-0003-1842-0348
Arsenyeva, Svetlana V. http://orcid.org/0000-0001-9803-0221
Matkava, Valeria G. http://orcid.org/0000-0002-3815-0608
Arefieva, Alia N. http://orcid.org/0000-0002-4156-5062
Kaleda, Mariya I. http://orcid.org/0000-0002-0513-6826
Smirnov, Alexandr V. http://orcid.org/0000-0001-7418-9369
Blank, Leonid M. http://orcid.org/0000-0002-4503-7750
Kostik, Mikhail M. http://orcid.org/0000-0002-1180-8086
- License Information
-
More Information
Article History
Received: 3 May 2023
Accepted: 4 July 2023
First Online: 29 August 2023
Declarations
:
: Written consent has been obtained from all parents/guardians of minors according to the declaration of Helsinki. Patients were observed and treated during real clinical practice. The local Ethics Committee of V.A. Nasonova Research Institute of Rheumatology approved the study (09 Dec 2019).
: All authors agree to publish the manuscript.
: Authors received spiker’s fees for lectures.I.Nikishina: Pfizer, Roche, Novartis, Sobi, MSD, R-Pharm, Ipsen.S.Arsenieva: Pfizer, Novartis, Ipsen.V.Matkava: Pfizer, Novartis, Ipsen.A.Arefieva: none.M.Kaleda: Pfizer, Roche.A.Smirnov: Pfizer, Novartis, Janssen, Eli Lilly, R-Pharm, Biocad.L.Blank: none.M.Kostik: none.
